Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Juxiang Xiao"'
Autor:
Jiujie Cui, Shukui Qin, Yuhong Zhou, Shuang Zhang, Xiaofeng Sun, Mingjun Zhang, Jiuwei Cui, Weijia Fang, Kangsheng Gu, Zhihua Li, Jufeng Wang, Xiaobing Chen, Jun Yao, Jun Zhou, Gang Wang, Yuxian Bai, Juxiang Xiao, Wensheng Qiu, Bangmao Wang, Tao Xia, Chunyue Wang, Li Kong, Jiajun Yin, Tao Zhang, Xionghu Shen, Deliang Fu, Chuntao Gao, Huan Wang, Quanren Wang, Liwei Wang
Publikováno v:
Signal Transduction and Targeted Therapy, Vol 9, Iss 1, Pp 1-9 (2024)
Abstract Liposomal irinotecan has shown promising antitumor activity in patients with advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) who have undergone prior gemcitabine-based therapies. This randomized, double-blind, parallel-control
Externí odkaz:
https://doaj.org/article/7a7dcbcd35414399b2d9715ea43ed0fe
Autor:
Jianming Xu, Yi Li, Qingxia Fan, Yongqian Shu, Lei Yang, Tongjian Cui, Kangsheng Gu, Min Tao, Xiuwen Wang, Chengxu Cui, Nong Xu, Juxiang Xiao, Quanli Gao, Yunpeng Liu, Tao Zhang, Yuxian Bai, Wei Li, Yiping Zhang, Guanghai Dai, Dong Ma, Jingdong Zhang, Chunmei Bai, Yunchao Huang, Wangjun Liao, Lin Wu, Xi Chen, Yan Yang, Junye Wang, Shoujian Ji, Hui Zhou, Yan Wang, Zhuo Ma, Yanqi Wang, Bo Peng, Jiya Sun, Christoph Mancao
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-12 (2022)
Patients with advanced esophageal cancer have poor prognosis and limited treatment options. This randomized, phase II trial compares the efficacy and safety of the anti-PD-1 antibody sintilimab versus chemotherapy in Chinese patients with esophageal
Externí odkaz:
https://doaj.org/article/ca3209d28c2d4a36b8c9ded73e1588cf
Autor:
Yan Song, Juxiang Xiao, Wentao Fang, Ping Lu, Qingxia Fan, Yongqian Shu, Jifeng Feng, Shu Zhang, Yi Ba, Yang Zhao, Ying Liu, Chunmei Bai, Yuxian Bai, Yong Tang, Jie He, Jing Huang
Publikováno v:
Cancer Biology & Medicine, Vol 18, Iss 2, Pp 562-568 (2021)
Objective: In this post-hoc analysis, we evaluated anlotinib treatment-induced hypertension as a potential predictive factor of efficacy in esophageal squamous cell carcinoma (ESCC) patients. Methods: A total of 109 patients enrolled in the anlotinib
Externí odkaz:
https://doaj.org/article/918d3c078c08402e916c3c0c0e0608a5
Autor:
Jing Huang, Juxiang Xiao, Wentao Fang, Ping Lu, Qingxia Fan, Yongqian Shu, Jifeng Feng, Shu Zhang, Yi Ba, Yang Zhao, Ying Liu, Chunmei Bai, Yuxian Bai, Yong Tang, Yan Song, Jie He
Publikováno v:
Cancer Medicine, Vol 10, Iss 5, Pp 1681-1689 (2021)
Abstract Background Currently, there are no randomized trials on the effect of antiangiogenic therapy in patients with esophageal squamous cell carcinoma (ESCC). The following study investigated the efficacy and safety of anlotinib in patients with a
Externí odkaz:
https://doaj.org/article/f3c438f2d33f4bc2b4f9d8510d6fe582
Publikováno v:
Cancer Cell International, Vol 17, Iss 1, Pp 1-14 (2017)
Abstract Background Breast cancer negatively affects women’s health worldwide. The tumour microenvironment plays a critical role in tumour initiation, proliferation, and metastasis. Cancer cells are traditionally grown in two-dimensional (2D) cultu
Externí odkaz:
https://doaj.org/article/cd118161160c4e019cdf0df9e234b555
Autor:
Lin Shen, Yanqiao Zhang, Jianjun Zou, Linna Wang, Yanfei Tai, Juxiang Xiao, Xianglin Yuan, Ying Cheng, Kangsheng Gu, Yanhong Deng, Jieer Ying, Feng Wang, Jia Wei, Zhi Peng
Supplementary Figure 1. Kaplan-Meier curves of OS in patients with tumor PD-L1 CPS >1 and those with tumor PD-L1 CPS {less than or equal to}1. Supplementary Table 1. Current List of Participating centers and investigators. Supplementary Table 2. Subs
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4199980b2eb4588e6a5a0f9fd769ad42
https://doi.org/10.1158/1078-0432.22479047
https://doi.org/10.1158/1078-0432.22479047
Autor:
Lin Shen, Yanqiao Zhang, Jianjun Zou, Linna Wang, Yanfei Tai, Juxiang Xiao, Xianglin Yuan, Ying Cheng, Kangsheng Gu, Yanhong Deng, Jieer Ying, Feng Wang, Jia Wei, Zhi Peng
Protocol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1eb7d92867ce0bb12f8f896dc4bb589d
https://doi.org/10.1158/1078-0432.22479044.v1
https://doi.org/10.1158/1078-0432.22479044.v1
Autor:
Lin Shen, Yanqiao Zhang, Jianjun Zou, Linna Wang, Yanfei Tai, Juxiang Xiao, Xianglin Yuan, Ying Cheng, Kangsheng Gu, Yanhong Deng, Jieer Ying, Feng Wang, Jia Wei, Zhi Peng
Purpose:Capecitabine plus oxaliplatin (CAPOX) is one of the standard first-line treatments for unresectable, advanced, or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. Camrelizumab shows promising antitumor activity in advan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41600b7b774170a4332bfc1baaccfd8b
https://doi.org/10.1158/1078-0432.c.6530120.v1
https://doi.org/10.1158/1078-0432.c.6530120.v1
Autor:
Shukui Qin, Zhendong Chen, Weijia Fang, Zhenggang Ren, Ruocai Xu, Baek-Yeol Ryoo, Zhiqiang Meng, Yuxian Bai, Xiaoming Chen, Xiufeng Liu, Juxiang Xiao, Gwo Fuang Ho, Yimin Mao, Xin Wang, Jieer Ying, Jianfeng Li, Wenyan Zhong, Yu Zhou, Abby B. Siegel, Chunyi Hao
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
PURPOSE We evaluated the efficacy and safety of pembrolizumab in patients from Asia with previously treated advanced hepatocellular carcinoma (HCC). METHODS In a double-blind, phase III trial, 453 patients with advanced HCC and progression during or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7c35e902b9433501308b1a4ee102dc2
https://pubmed.ncbi.nlm.nih.gov/36455168
https://pubmed.ncbi.nlm.nih.gov/36455168
Autor:
Jifeng Feng, Chunmei Bai, Yang Zhao, Yongqian Shu, Qingxia Fan, Shu Zhang, Wentao Fang, Yuxian Bai, Jing Huang, Yan Song, Ping Lu, Jie He, Juxiang Xiao, Ying Liu, Yong Tang, Yi Ba
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 5, Pp 1681-1689 (2021)
Cancer Medicine, Vol 10, Iss 5, Pp 1681-1689 (2021)
Background Currently, there are no randomized trials on the effect of antiangiogenic therapy in patients with esophageal squamous cell carcinoma (ESCC). The following study investigated the efficacy and safety of anlotinib in patients with advanced E
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c8f8fb0101210b732558304946c01d5
https://doi.org/10.1002/cam4.3771
https://doi.org/10.1002/cam4.3771